QLT Announces The Initiation Of A Phase I Trial Of Its Synthetic Retinoid Product

QLT Inc. (NASDAQ: QLTI; TSX: QLT) announced that it has initiated a Phase I safety study in healthy adults of QLT091001, an orally administered synthetic retinoid replacement therapy for 11-cis-retinal, which is a key biochemical component of the visual retinoid cycle. The drug is being developed for the potential treatment of Leber's Congenital Amourosis (LCA), an inherited progressive retinal degenerative disease that leads to retinal dysfunction and visual impairment beginning at birth. The Phase I study is an open-label, single center, ascending dose trial that will determine the safety and tolerance of multiple administrations of the synthetic retinoid drug in approximately 18 healthy adult volunteers. Participants will be enrolled in up to 6 cohorts of increasing doses. "We believe our retinoid synthetic drug program is... [read full story]